CustoMED, a leader in AI-driven, surgeon-first orthopedic technologies, announced the successful close of a $6 million seed funding round. The round included participation from Longevity Venture Partners, Varana Capital, Flag Capital, the Israel Innovation Authority, a leading orthopedic implant company, and Avishai Abrahami, Co-founder and CEO of Wix.
The funding will accelerate CustoMED’s expansion into additional automated orthopedic indications, support regulatory milestones in the United States and Europe—with approvals expected in 2026—and enable global deployment of its on-demand manufacturing model.
CustoMED’s cloud-based platform combines artificial intelligence and 3D printing to convert pre-operative imaging into patient-specific surgical tools and implants instantly. The platform delivers precise, ready-to-use surgical components within minutes rather than weeks, allowing for faster, safer, and more personalized orthopedic surgeries. The patient-specific devices can be produced onsite or via certified partners and integrate seamlessly into existing surgical workflows, reducing intraoperative errors and enhancing outcomes.
Already used in hundreds of successful surgeries globally, CustoMED’s technology is transforming what was once a bespoke process into a scalable, routine part of modern medicine. By giving surgeons complete creative and clinical control, the company is redefining orthopedic precision and accessibility.
Founded by Dr. Amit Zabatani, Or Benifla, and Alon Jacobi, CustoMED originated from Sheba Medical Center’s 3D Printing & Innovation Lab, launched in 2018 by Dr. Dina Orkin in collaboration with the founders. The lab has played a key role in integrating 3D printing into clinical workflows across Sheba’s departments, and CustoMED continues this legacy as part of ARC Innovation, Sheba’s global healthcare innovation ecosystem.
The company’s next phase focuses on scaling its cloud platform across primary orthopedic specialties, leveraging AI automation and advanced printing to shorten surgical preparation times and improve procedural predictability. CustoMED’s approach aligns with ARC’s mission to accelerate clinician-led innovation that translates directly into real-world medical impact.
KEY QUOTES:
“CustoMED’s patient-specific surgical tools enable more precise orthopedic surgeries through affordable, real-time solutions delivered directly into the operating room. By putting scalable, personalized technology directly in surgeons’ hands, our mission is to make computer-guided surgery fast, accessible, and routine, transforming what was once a boutique process into standard of care for every patient.”
Or Benifla, Co-Founder, CustoMED
“CustoMED is embedding precision and surgeon-directed tools into everyday workflows, shortening the path from imaging to the operating room while preserving governance, quality, and safety. The company exemplifies ARC’s mission to translate clinical insight into scalable, real-world impact.”
Prof. Eyal Zimlichman, Founder and Director of ARC Innovation and Chief Innovation, Transformation, and AI Officer, Sheba Medical Center
“We were immediately impressed by the ARC team’s world-class experience and CustoMED’s mission to improve surgical performance and patient outcomes. CustoMED’s platform gives surgeons everywhere access to personalized planning and surgical tools that can raise the standard of care in orthopedic surgery.”
Raissa Hacohen, Managing Partner, Longevity Venture Partners
